PTC upgrades its ALM portfolio with Codebeamer 3.2, AI 1.0 and Pure Variants 7.2 to boost traceability, change control and ...

PTC today announced advancements to its application lifecycle management (ALM) portfolio with the release of the Codebeamer® 3.2, Codebeamer AI 1.0, and Pure Variantstm 7.2 solutions. These updates ...

现代产品开发中，软件团队常常在需求管理、测试追踪和合规流程中疲于奔命，分散的工具与断裂的数据流拖慢创新步伐，PTC Codebeamer正是为了解决这些痛点而生。 这款产品源自德国Intland Software (2002年创立)，2022年被PTC收购。收购后，PTC加大投入并整合其配置管理工具，形成如今更强大的Codebeamer。

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States ...

More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US. The FDA has approved PTC's ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

In a potentially pivotal trial, PTC Therapeutics' experimental therapy for Huntington's disease (HD) met its primary endpoint, but questions about the data have raised doubts about the company's ...